You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


GSK and Alector ink neurodegenerative diseases partnership

British drugmaker GlaxoSmithKline (GSK) has announced a new global collaboration with Alector to develop and commercialise two monoclonal antibodies (mAb) for the treatment of neurodegenerative diseases.